Amylyx Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMLX Nasdaq 2830 amylyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amylyx Pharmaceuticals, Inc.

March 2025's Top Penny Stocks To Watch - Mar 6th, 2025 11:05 am
Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Mar 5th, 2025 3:01 pm
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - Mar 4th, 2025 11:00 am
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Feb 25th, 2025 2:00 pm
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - Feb 24th, 2025 2:00 pm
Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 10th, 2025 2:00 pm
February 2025's Promising Penny Stocks On US Exchanges - Feb 5th, 2025 1:06 pm
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? - Jan 31st, 2025 5:00 pm
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Jan 21st, 2025 2:00 pm
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Jan 10th, 2025 1:26 pm
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Jan 10th, 2025 12:30 am
Cerus And 2 Other US Penny Stocks With Promising Potential - Jan 6th, 2025 5:07 pm
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer - Jan 6th, 2025 2:00 pm
Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? - Dec 30th, 2024 7:52 pm
Amylyx announces design of LUCIDITY clinical trial - Dec 5th, 2024 12:35 pm
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia - Dec 4th, 2024 12:30 pm
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Nov 27th, 2024 2:00 pm
Amylyx Pharmaceuticals Third Quarter 2024 Earnings: US$1.07 loss per share (vs US$0.31 profit in 3Q 2023) - Nov 9th, 2024 2:56 pm
Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Nov 8th, 2024 7:11 am
Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call - Nov 8th, 2024 6:33 am